Reduction of Direct Health Costs Associated with Pertussis Vaccination with Acellular Vaccines in Children Aged 0-9 Years with Pertussis in Catalonia (Spain)
- PMID: 29761340
- PMCID: PMC6393282
- DOI: 10.1007/s41669-018-0081-4
Reduction of Direct Health Costs Associated with Pertussis Vaccination with Acellular Vaccines in Children Aged 0-9 Years with Pertussis in Catalonia (Spain)
Abstract
Objectives: The aim of this study was to assess direct health costs in children with pertussis aged 0-9 years who were vaccinated, partially vaccinated, and unvaccinated during childhood, and to assess the association between pertussis costs and pertussis vaccination in Catalonia (Spain) in 2012-2013.
Methods: Direct healthcare costs included pertussis treatment, pertussis detection, and preventive chemotherapy of contacts. Pertussis patients were considered vaccinated when they had received 4-5 doses, and unvaccinated or partially vaccinated when they had received 0-3 doses of vaccine. The Chi square test and the odds ratios were used to compare percentages and the t test was used to compare mean pertussis costs in different groups, considering a p < 0.05 as statistically significant. The correlation between pertussis costs and study variables was assessed using the Spearman's ρ, with a p < 0.05 as statistically significant. Multiple linear regression analysis (IBM-SPSS program) was used to quantify the association of pertussis vaccination and other study variables with pertussis costs.
Results: Vaccinated children with pertussis aged 0-9 years had significantly lower odds ratios of hospitalizations (OR 0.02, p < 0.001), laboratory confirmation (OR 0.21, p < 0.001), and severe disease (OR 0.02, p < 0.001) than unvaccinated or partially vaccinated children with pertussis of the same age. Mean direct healthcare costs were significantly lower (p < 0.001) in vaccinated patients (€190.6) than in unvaccinated patients (€3550.8), partially vaccinated patients (€1116.9), and unvaccinated/partially vaccinated patients (€2330). Multivariable linear regression analysis showed that pertussis vaccination with 4-5 doses was associated with a non-significant reduction of pertussis costs of €107.9 per case after taking into account the effect of other study variables, and €200 per case after taking into account pertussis severity.
Conclusions: Direct healthcare costs were lower in children with pertussis aged 0-9 years vaccinated with 4-5 doses of acellular vaccines than in unvaccinated or partially vaccinated children with pertussis of the same age.
Conflict of interest statement
PP-R, EN, PG, GC, AD, MJ, CM-A, and PB declare that they have no conflict of interest.
Figures
References
-
- National Center for Immunization and Respiratory Diseases, CDC. 2016 Provisional pertussis surveillance report; 2017. https://www.cdc.gov/pertussis/downloads/pertuss-surv-report-2016-provisi.... Accessed 2 Feb 2018.
-
- Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Red Nacional de Vigilancia Epidemiológica. Protocolos de enfermedades de declaración obligatoria: Tos ferina. Madrid. Madrid: Centro Nacional de Epidemiologia; 2013. pp. 624–639.
-
- Grupo de Trabajo Tos Ferina 2012 de la Ponencia de Programas y Registro de Vacunaciones. Revisión del programa de vacunación frente a tos ferina en España. Madrid: Comisión de Salud Pública del Consejo Interterritorial del Sistema Nacional de Salud. Ministerio de Sanidad, Servicios Sociales e Igualdad; 2013.
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
